James Nelson
Psychiatry · Houston, TXNPI 1184950552
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,093, 8.1 times the $260 reported in 2019.
Across 163 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$668
- Axsome Therapeutics, Inc.$486
- AbbVie$410
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$330
- Johnson & Johnson$324
- Teva Pharmaceuticals USA, Inc.$249
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 13 | $668 |
| Axsome Therapeutics, Inc. | 13 | $486 |
| AbbVie | 24 | $410 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $330 |
| Johnson & Johnson | 7 | $324 |
| Teva Pharmaceuticals USA, Inc. | 10 | $249 |
| Tris Pharma Inc | 9 | $196 |
| Supernus Pharmaceuticals, Inc. | 4 | $175 |
| Idorsia Pharmaceuticals US Inc | 6 | $169 |
| Lundbeck LLC | 7 | $149 |
| Neos Therapeutics, LP | 6 | $144 |
| Otsuka America Pharmaceutical, Inc. | 7 | $144 |
| Corium, LLC | 8 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 5 | $111 |
| Noven Therapeutics, LLC | 5 | $88 |
| Collegium Pharmaceutical, Inc. | 4 | $74 |
| Almatica Pharma LLC | 3 | $54 |
| Rhodes Pharmaceuticals L.p. | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Adlon Therapeutics L.p. | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,155 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 14 | $353 |
| Clonazepam | 17 | $135 |
| Trazodone Hcl | 16 | $53 |
| Clonidine Hcl | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.